AFA
MIST icon

Alta Fundamental Advisers’s Milestone Pharmaceuticals MIST Stock Holding History

Alta Fundamental Advisers’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,398,977
Closed -$2.71M – 31
2025
Q2 		$2.71M Sell
1,398,977
-28,502
-2% -$38K 1.39% 20
2025
Q1 		$1.14M Sell
1,427,479
-1,231,110
-46% -$2.45M 0.73% 18
2024
Q4 		$6.27M Hold
2,658,589
– – 1.88% 15
2024
Q3 		$4.04M Hold
2,658,589
– – 1.16% 18
2024
Q2 		$3.51M Buy
2,658,589
+287,300
+12% +$462K 1.11% 17
2024
Q1 		$4.24M Buy
2,371,289
+700,000
+42% +$1.14M 1.61% 12
2023
Q4 		$2.79M Buy
1,671,289
+495,100
+42% +$1.34M 1.26% 13
2023
Q3 		$3.65M Buy
1,176,189
+278,228
+31% +$865K 1.74% 9
2023
Q2 		$2.56M Hold
897,961
– – 1.25% 10
2023
Q1 		$3.54M Buy
897,961
+332,500
+59% +$1.22M 1.5% 12
2022
Q4 		$2.24M Buy
+565,461
New +$2.98M 0.97% 14

Other funds holding MIST

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Alta Fundamental Advisers's MIST Position: Q3 2025 in Review

Alta Fundamental Advisers sold out of Milestone Pharmaceuticals (MIST) in Q3 2025, closing a stake of 1,398,977 shares — an estimated $2.71M sold.

Alta Fundamental Advisers first reported a position in MIST in Q4 2022 and held it in 11 quarters. The position peaked at $6.27M in Q4 2024. 61 funds tracked by Wall St. Rank hold MIST as of Q3 2025.

  • Alta Fundamental Advisers reported no remaining Milestone Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Alta Fundamental Advisers sold 1,398,977 Milestone Pharmaceuticals shares in Q3 2025, an estimated $2.71M.
  • Alta Fundamental Advisers first reported a position in Milestone Pharmaceuticals in Q4 2022 and held it in 11 quarters.
  • Alta Fundamental Advisers's Milestone Pharmaceuticals position peaked at $6.27M in Q4 2024.
  • 61 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q3 2025.

Based on Alta Fundamental Advisers's 13F filing for Q3 2025, filed 13 Nov 2025.